Highlights from day 1
Dr Mariana Brandao (HUB – Institut Jules Bordet) brings from a rainy Copenhagen the first report on the highlights of day 1 at the ELCC congress.
She briefly describes three studies. The Apple study investigated the feasibility of longitudinal plasma EGFR T790M monitoring and the best sequencing strategy from gefitinib to osimertinib. The Chrysalis study examined the efficacy of amivantamab in EGFR Exon 20 insertion-mutated NSCLC progressing on platinum chemotherapy. And finally, Dr Brandao discusses the patient-reported outcomes from the CodeBreaK 200 phase 3 trial comparing sotorasib versus docetaxel in KRAS G12C-mutated NSCLC.
With the support of:
No Comment! Be the first one.